Keap1 loss-of-function and/or Nrf2 gain-of-function mutations were predictors of poor clinical outcome in different tumour aetiologies, such as in HCC, and ovarian, lung, endometrial, breast, and head and neck cancers [25,26]. This evidence concerns the gene NFE2L2 and hepatocellular carcinoma.